Stocks and Investing Stocks and Investing
Wed, March 27, 2024

Kostas Biliouris Maintained (BEAM) at Buy and Held Target at $57 on, Mar 27th, 2024


Published on 2024-10-28 09:56:36 - WOPRAI, Kostas Biliouris
  Print publication without navigation


Kostas Biliouris of BMO Capital, Maintained "Beam Therapeutics Inc." (BEAM) at Buy and Held Target at $57 on, Mar 27th, 2024.

Kostas has made no other calls on BEAM in the last 4 months.



There are 5 other peers that have a rating on BEAM. Out of the 5 peers that are also analyzing BEAM, 4 agree with Kostas's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Gena Wang of "Barclays" Maintained at Hold with Increased Target to $42 on, Wednesday, February 28th, 2024
  • Luca Issi of "RBC Capital" Maintained at Hold with Increased Target to $35 on, Wednesday, February 28th, 2024
  • Greg Harrison of "B of A Securities" Downgraded from Strong Buy to Hold and Held Target at $35 on, Friday, December 15th, 2023
  • Michael Yee of "Jefferies" Downgraded from Strong Buy to Hold and Decreased Target to $30 on, Friday, December 8th, 2023


This is the rating of the analyst that currently disagrees with Kostas


  • Eric Joseph of "JP Morgan" Upgraded from Hold to Buy and Increased Target to $40 on, Monday, January 29th, 2024
Contributing Sources